-The Economic Times A growing number of countries are adopting India's intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health. Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions. Last month, China amended its IP laws, allowing local companies to produce low-cost versions...

-Down to Earth Traders say Food Safety and Standards Act rolls out red carpet for multinationals The Food Safety and Standards Act (FSSA) of 2006 has not gone down well with food business operators. They say sections of the Act dealing with licensing, registration, hygiene standards, penalty provisions and powers of food safety inspectors are “draconian”. FSSA, which came into force in August last year, replaces the Prevention of Food Adulteration Act (PFA)...

-Down to Earth Food safety authority approves scientific panel's recommendations for regulating honey quality India has inched closer to regulating antibiotics in honey with the apex food safety body of the country approving the recommendations of its own scientific panel and committee on fixing rules for antibiotics in honey. The recommendations put forth by the scientific panel, which says antibiotics should not be used at any stage of honey production, has been...

The ASCI report says there is ample evidence of “market dominance” in specific media markets, but the government has ignored the report for three years. A ministry official tells PARANJOY GUHA THAKURTA that it is unlikely to be implemented. A report prepared by an independent institution recommending imposition of cross-media ownership restrictions recently entered the public domain nearly three years after it was submitted,  following a rebuke to the government by...

-The Economic Times   Pushed to the wall by an overly cautious drug regulator and an alarmist Indian government, clinical trial companies are looking at South East Asian countries to expand their business and escape the red tape of Indian authorities.  Clinical research companies (CROs), that were aspiring to become billion- dollar companies by 2010, had to rework their plans after a Parliamentary Standing Committee report questioned the allegedly unfair and unethical trials...